You are here

  • Home
  • Archive
  • Volume 7, Issue 6
  • Effects of hormone therapy on quality of life in postmenopausal women with CAD differed according to menopausal symptoms

Article Text

Article menu
Download PDFPDF
Therapeutics
Effects of hormone therapy on quality of life in postmenopausal women with CAD differed according to menopausal symptoms

https://doi.org/10.1136/ebm.7.6.171

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) JAMA 287, 591; Hlatky MA, Boothroyd D, Vittinghoff E, et al, for the HERS Research Group.. Quality of life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial.. Feb 6;. :. –7.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: Does hormone therapy (HT) improve health-related quality of life (HRQL) in postmenopausal women with coronary artery disease (CAD)?

    Design

    Randomised {allocation concealed*}†, blinded {patients, clinicians, data collectors, and outcome assessors}‡*, placebo-controlled trial with follow up to 3 years.

    Setting

    Outpatient and community settings at 20 US clinical centres.

    Patients

    2763 postmenopausal women <80 years of age (mean age 67 y) with documented CAD (previous myocardial infarction [MI], >50% luminal narrowing of a major vessel on angiography, or a previous coronary revascularisation procedure). Exclusion criteria were MI or revascularisation procedure in the past 6 months, previous hysterectomy, contraindications to HT, HT in the previous 3 months, or life-threatening illness. 2762 patients (99.9%) were included in the analysis; 2246 (81%) had HRQL data for all time points (baseline, 4 mo, 1 y, and 3 y).

    Intervention

    1380 women were allocated to HT (0.625 mg of conjugated equine oestrogens and 2.5 mg of medroxyprogesterone acetate [Prempro, …

    View Full Text

    Footnotes

    • A modified version of this abstract also appears in Evidence-Based Mental Health and Evidence-Based Nursing.

    • Source of funding: Wyeth-Ayerst Research.

    • For correspondence: Dr MA Hlatky, Stanford University, School of Medicine, Stanford, CA, USA. E-mail hlatky{at}stanford.edu

    • ↵† Hulley S, Grady D, Bush T, et al. JAMA 1998;280:605–13.

    • ↵‡ Information provided by author.

    • ↵* See glossary.